E
Edward T.H. Yeh
High Impact
Chairman
faculty
Department Chairs, College of Medicine
87 h-index
276 pubs
28,873 cited
Research Areas
Biography and Research Information
OverviewAI-generated summary
Edward T.H. Yeh leads a research group at the University of Arkansas for Medical Sciences, where he serves as Chairman of the Department Chairs in the College of Medicine. His scholarship metrics include an h-index of 87, with 276 total publications and over 28,000 citations, designating him as a highly cited researcher. Yeh's work investigates molecular mechanisms underlying various physiological and pathological processes. Recent publications from his group have focused on the role of SUMO-specific proteases (SENP2) in regulating ion channel function, neurogenesis, and adrenal cortex development. His research also explores the regulation of Toll-like receptor 4 (TLR4) signaling through specific protein interactions and phosphorylation events, with implications for conditions such as acute lung injury. Additionally, his group has examined the involvement of dipeptidylpeptidase 4 in the survival and stemness of acute myeloid leukemia stem cells, and the contribution of Kv7 channel activity in the central amygdala to sympathetic outflow in hypertension. Key collaborators include Hui-Ming Chang and J.C. Hsu, both from the University of Arkansas for Medical Sciences.
Metrics
- h-index: 87
- Publications: 276
- Citations: 28,873
Selected Publications
-
PP4 modulates macrophage-neutrophil crosstalk to restrict CCL5 -driven NETosis in sepsis (2026)
-
CYLD links the TRAF6/sNASP axis to TLR4 signaling in sepsis-induced acute lung injury (2025)
-
Microglia‐Mediated Synaptic Dysfunction Contributes to Chemotherapy‐Related Cognitive Impairment (2025)
-
Abstract 12348: Targeted Degradation of Topoisomerase 2b by Dexrazoxane for Prevention of Doxorubicin-Induced Cardiotoxicity: Dose and Time Course Study in Human (2023)
-
Lactate: an intracellular metabolite regulates cell cycle progression (2023)
-
Corticotropin-releasing hormone neurons in the central nucleus of amygdala are required for chronic stress-induced hypertension (2023)
-
Promises and challenges of machine learning for device therapy in heart failure (2023)
-
Dipeptidylpeptidase 4 promotes survival and stemness of acute myeloid leukemia stem cells (2023)
-
Loss of SUMO-specific protease 2 causes isolated glucocorticoid deficiency by blocking adrenal cortex zonal transdifferentiation in mice (2022)
-
Signaling pathways involved in <scp>NMDA</scp>‐induced suppression of M‐channels in corticotropin‐releasing hormone neurons in central amygdala (2022)
-
Dependence of Acute Myeloid Leukemia Development on Membrane Protein Dipeptidyl Peptidase 4 (2022)
-
PEP-sNASP Peptide Alleviates LPS-Induced Acute Lung Injury Through the TLR4/TRAF6 Axis (2022)
-
Loss of SUMO-specific protease 2 causes isolated glucocorticoid deficiency by blocking adrenal cortex zonal transdifferentiation (2022)
-
Abstract 9710: Prevention of Doxorubicin-Induced Cardiotoxicity Through Targeted Degradation of Topoisomerase 2b (2021)
-
Regulation of TLR4 signaling through the TRAF6/sNASP axis by reversible phosphorylation mediated by CK2 and PP4 (2021)
Grants & Funding
- Doxorubicin-induced Cardiotoxicity: The Role of Topoisomerase 2b NIH/Nat. Heart, Lung & Blood Institute Principal Investigator
- PATHOBIOCHEMISTRY OF ACUTE PROMYELOCYTIC LEUKEMIA NIH Principal Investigator
- Doxorubicin-induced Cardiotoxicity: The Role of Topoisomerase 2b NIH/Nat. Heart, Lung & Blood Institute Principal Investigator
- Prevention of Heart Failure induced by Doxorubicin with Early Administration of Dexrazoxane NIH/Nat. Heart, Lung & Blood Institute Co-Investigator
- Doxorubicin-induced Cardiotoxicity: the Role of Topoisomerase 2b NIH Principal Investigator
- De-SUMOylation and the Hypoxic Response NIH Principal Investigator
- STUDIES OF THE SENTRIN FAMILY OF UBIQUITIN-LIKE PROTEINS NIH Principal Investigator
- PATHOBIOLOGY OF PAROXYSMAL NOCTURNAL HEMOGLOBINURIA NIH Principal Investigator
Collaboration Network
Top Collaborators
Hui‐Ming Chang
Arkansas Department of Agriculture
9 shared publications
In database
- Impaired Kv7 channel activity in the central amygdala contributes to elevated sympathetic outflow in hypertension
- Dipeptidylpeptidase 4 promotes survival and stemness of acute myeloid leukemia stem cells
- Signaling pathways involved in <scp>NMDA</scp>‐induced suppression of M‐channels in corticotropin‐releasing hormone neurons in central amygdala
- Microglia‐Mediated Synaptic Dysfunction Contributes to Chemotherapy‐Related Cognitive Impairment
- Prevention of Heart Failure Induced by Doxorubicin with Early Administration of Dexrazoxane (PHOENIX Study): dose response and time course of dexrazoxane-induced degradation of topoisomerase 2b
Showing 5 of 9 shared publications
Chun‐Te Chen
8 shared publications
- Data from Dual Targeting of Tumor Angiogenesis and Chemotherapy by Endostatin–Cytosine Deaminase–Uracil Phosphoribosyltransferase
- Supplementary Methods from Dual Targeting of Tumor Angiogenesis and Chemotherapy by Endostatin–Cytosine Deaminase–Uracil Phosphoribosyltransferase
- Supplementary Figure Legends 1-4 from Dual Targeting of Tumor Angiogenesis and Chemotherapy by Endostatin–Cytosine Deaminase–Uracil Phosphoribosyltransferase
- Supplementary Figures 1-4 from Dual Targeting of Tumor Angiogenesis and Chemotherapy by Endostatin–Cytosine Deaminase–Uracil Phosphoribosyltransferase
- Supplementary Figures 1-4 from Dual Targeting of Tumor Angiogenesis and Chemotherapy by Endostatin–Cytosine Deaminase–Uracil Phosphoribosyltransferase
Showing 5 of 8 shared publications
Hirohito Yamaguchi
8 shared publications
- Data from Dual Targeting of Tumor Angiogenesis and Chemotherapy by Endostatin–Cytosine Deaminase–Uracil Phosphoribosyltransferase
- Supplementary Methods from Dual Targeting of Tumor Angiogenesis and Chemotherapy by Endostatin–Cytosine Deaminase–Uracil Phosphoribosyltransferase
- Supplementary Figure Legends 1-4 from Dual Targeting of Tumor Angiogenesis and Chemotherapy by Endostatin–Cytosine Deaminase–Uracil Phosphoribosyltransferase
- Supplementary Figures 1-4 from Dual Targeting of Tumor Angiogenesis and Chemotherapy by Endostatin–Cytosine Deaminase–Uracil Phosphoribosyltransferase
- Supplementary Figures 1-4 from Dual Targeting of Tumor Angiogenesis and Chemotherapy by Endostatin–Cytosine Deaminase–Uracil Phosphoribosyltransferase
Showing 5 of 8 shared publications
Hong-Jen Lee
8 shared publications
- Data from Dual Targeting of Tumor Angiogenesis and Chemotherapy by Endostatin–Cytosine Deaminase–Uracil Phosphoribosyltransferase
- Supplementary Methods from Dual Targeting of Tumor Angiogenesis and Chemotherapy by Endostatin–Cytosine Deaminase–Uracil Phosphoribosyltransferase
- Supplementary Figure Legends 1-4 from Dual Targeting of Tumor Angiogenesis and Chemotherapy by Endostatin–Cytosine Deaminase–Uracil Phosphoribosyltransferase
- Supplementary Figures 1-4 from Dual Targeting of Tumor Angiogenesis and Chemotherapy by Endostatin–Cytosine Deaminase–Uracil Phosphoribosyltransferase
- Supplementary Figures 1-4 from Dual Targeting of Tumor Angiogenesis and Chemotherapy by Endostatin–Cytosine Deaminase–Uracil Phosphoribosyltransferase
Showing 5 of 8 shared publications
Yi Du
8 shared publications
- Data from Dual Targeting of Tumor Angiogenesis and Chemotherapy by Endostatin–Cytosine Deaminase–Uracil Phosphoribosyltransferase
- Supplementary Methods from Dual Targeting of Tumor Angiogenesis and Chemotherapy by Endostatin–Cytosine Deaminase–Uracil Phosphoribosyltransferase
- Supplementary Figure Legends 1-4 from Dual Targeting of Tumor Angiogenesis and Chemotherapy by Endostatin–Cytosine Deaminase–Uracil Phosphoribosyltransferase
- Supplementary Figures 1-4 from Dual Targeting of Tumor Angiogenesis and Chemotherapy by Endostatin–Cytosine Deaminase–Uracil Phosphoribosyltransferase
- Supplementary Figures 1-4 from Dual Targeting of Tumor Angiogenesis and Chemotherapy by Endostatin–Cytosine Deaminase–Uracil Phosphoribosyltransferase
Showing 5 of 8 shared publications
Heng‐Huan Lee
8 shared publications
- Data from Dual Targeting of Tumor Angiogenesis and Chemotherapy by Endostatin–Cytosine Deaminase–Uracil Phosphoribosyltransferase
- Supplementary Methods from Dual Targeting of Tumor Angiogenesis and Chemotherapy by Endostatin–Cytosine Deaminase–Uracil Phosphoribosyltransferase
- Supplementary Figure Legends 1-4 from Dual Targeting of Tumor Angiogenesis and Chemotherapy by Endostatin–Cytosine Deaminase–Uracil Phosphoribosyltransferase
- Supplementary Figures 1-4 from Dual Targeting of Tumor Angiogenesis and Chemotherapy by Endostatin–Cytosine Deaminase–Uracil Phosphoribosyltransferase
- Supplementary Figures 1-4 from Dual Targeting of Tumor Angiogenesis and Chemotherapy by Endostatin–Cytosine Deaminase–Uracil Phosphoribosyltransferase
Showing 5 of 8 shared publications
Weiya Xia
8 shared publications
- Data from Dual Targeting of Tumor Angiogenesis and Chemotherapy by Endostatin–Cytosine Deaminase–Uracil Phosphoribosyltransferase
- Supplementary Methods from Dual Targeting of Tumor Angiogenesis and Chemotherapy by Endostatin–Cytosine Deaminase–Uracil Phosphoribosyltransferase
- Supplementary Figure Legends 1-4 from Dual Targeting of Tumor Angiogenesis and Chemotherapy by Endostatin–Cytosine Deaminase–Uracil Phosphoribosyltransferase
- Supplementary Figures 1-4 from Dual Targeting of Tumor Angiogenesis and Chemotherapy by Endostatin–Cytosine Deaminase–Uracil Phosphoribosyltransferase
- Supplementary Figures 1-4 from Dual Targeting of Tumor Angiogenesis and Chemotherapy by Endostatin–Cytosine Deaminase–Uracil Phosphoribosyltransferase
Showing 5 of 8 shared publications
Wen-Hsuan Yu
8 shared publications
- Data from Dual Targeting of Tumor Angiogenesis and Chemotherapy by Endostatin–Cytosine Deaminase–Uracil Phosphoribosyltransferase
- Supplementary Methods from Dual Targeting of Tumor Angiogenesis and Chemotherapy by Endostatin–Cytosine Deaminase–Uracil Phosphoribosyltransferase
- Supplementary Figure Legends 1-4 from Dual Targeting of Tumor Angiogenesis and Chemotherapy by Endostatin–Cytosine Deaminase–Uracil Phosphoribosyltransferase
- Supplementary Figures 1-4 from Dual Targeting of Tumor Angiogenesis and Chemotherapy by Endostatin–Cytosine Deaminase–Uracil Phosphoribosyltransferase
- Supplementary Figures 1-4 from Dual Targeting of Tumor Angiogenesis and Chemotherapy by Endostatin–Cytosine Deaminase–Uracil Phosphoribosyltransferase
Showing 5 of 8 shared publications
Jennifer L. Hsu
8 shared publications
- Data from Dual Targeting of Tumor Angiogenesis and Chemotherapy by Endostatin–Cytosine Deaminase–Uracil Phosphoribosyltransferase
- Supplementary Methods from Dual Targeting of Tumor Angiogenesis and Chemotherapy by Endostatin–Cytosine Deaminase–Uracil Phosphoribosyltransferase
- Supplementary Figure Legends 1-4 from Dual Targeting of Tumor Angiogenesis and Chemotherapy by Endostatin–Cytosine Deaminase–Uracil Phosphoribosyltransferase
- Supplementary Figures 1-4 from Dual Targeting of Tumor Angiogenesis and Chemotherapy by Endostatin–Cytosine Deaminase–Uracil Phosphoribosyltransferase
- Supplementary Figures 1-4 from Dual Targeting of Tumor Angiogenesis and Chemotherapy by Endostatin–Cytosine Deaminase–Uracil Phosphoribosyltransferase
Showing 5 of 8 shared publications
Chia‐Jui Yen
8 shared publications
- Data from Dual Targeting of Tumor Angiogenesis and Chemotherapy by Endostatin–Cytosine Deaminase–Uracil Phosphoribosyltransferase
- Supplementary Methods from Dual Targeting of Tumor Angiogenesis and Chemotherapy by Endostatin–Cytosine Deaminase–Uracil Phosphoribosyltransferase
- Supplementary Figure Legends 1-4 from Dual Targeting of Tumor Angiogenesis and Chemotherapy by Endostatin–Cytosine Deaminase–Uracil Phosphoribosyltransferase
- Supplementary Figures 1-4 from Dual Targeting of Tumor Angiogenesis and Chemotherapy by Endostatin–Cytosine Deaminase–Uracil Phosphoribosyltransferase
- Supplementary Figures 1-4 from Dual Targeting of Tumor Angiogenesis and Chemotherapy by Endostatin–Cytosine Deaminase–Uracil Phosphoribosyltransferase
Showing 5 of 8 shared publications
Gabriel N. Hortobágyi
8 shared publications
- Data from Dual Targeting of Tumor Angiogenesis and Chemotherapy by Endostatin–Cytosine Deaminase–Uracil Phosphoribosyltransferase
- Supplementary Methods from Dual Targeting of Tumor Angiogenesis and Chemotherapy by Endostatin–Cytosine Deaminase–Uracil Phosphoribosyltransferase
- Supplementary Figure Legends 1-4 from Dual Targeting of Tumor Angiogenesis and Chemotherapy by Endostatin–Cytosine Deaminase–Uracil Phosphoribosyltransferase
- Supplementary Figures 1-4 from Dual Targeting of Tumor Angiogenesis and Chemotherapy by Endostatin–Cytosine Deaminase–Uracil Phosphoribosyltransferase
- Supplementary Figures 1-4 from Dual Targeting of Tumor Angiogenesis and Chemotherapy by Endostatin–Cytosine Deaminase–Uracil Phosphoribosyltransferase
Showing 5 of 8 shared publications
Mien‐Chie Hung
8 shared publications
- Data from Dual Targeting of Tumor Angiogenesis and Chemotherapy by Endostatin–Cytosine Deaminase–Uracil Phosphoribosyltransferase
- Supplementary Methods from Dual Targeting of Tumor Angiogenesis and Chemotherapy by Endostatin–Cytosine Deaminase–Uracil Phosphoribosyltransferase
- Supplementary Figure Legends 1-4 from Dual Targeting of Tumor Angiogenesis and Chemotherapy by Endostatin–Cytosine Deaminase–Uracil Phosphoribosyltransferase
- Supplementary Figures 1-4 from Dual Targeting of Tumor Angiogenesis and Chemotherapy by Endostatin–Cytosine Deaminase–Uracil Phosphoribosyltransferase
- Supplementary Figures 1-4 from Dual Targeting of Tumor Angiogenesis and Chemotherapy by Endostatin–Cytosine Deaminase–Uracil Phosphoribosyltransferase
Showing 5 of 8 shared publications
Typhanie Dumontet
Centre National de la Recherche Scientifique (FR)
5 shared publications
- Loss of SUMO-specific protease 2 causes isolated glucocorticoid deficiency by blocking adrenal cortex zonal transdifferentiation in mice
- L’excès de SUMOylation altère l’homéostasie postnatale du cortex surrénalien et conduit à un déficit isolé en glucocorticoïde
- Loss of SUMO-specific protease 2 causes isolated glucocorticoid deficiency by blocking adrenal cortex zonal transdifferentiation
- Loss of SUMO-specific protease 2 causes isolated glucocorticoid deficiency by blocking adrenal cortex zonal transdifferentiation
- Loss of SUMO-specific protease 2 leads to adrenal insufficiency limited to glucocorticoids
Eric Pussard
Inserm (FR)
5 shared publications
- Loss of SUMO-specific protease 2 causes isolated glucocorticoid deficiency by blocking adrenal cortex zonal transdifferentiation in mice
- L’excès de SUMOylation altère l’homéostasie postnatale du cortex surrénalien et conduit à un déficit isolé en glucocorticoïde
- Loss of SUMO-specific protease 2 causes isolated glucocorticoid deficiency by blocking adrenal cortex zonal transdifferentiation
- Loss of SUMO-specific protease 2 causes isolated glucocorticoid deficiency by blocking adrenal cortex zonal transdifferentiation
- Loss of SUMO-specific protease 2 leads to adrenal insufficiency limited to glucocorticoids
Isabelle Sahut‐Barnola
Centre National de la Recherche Scientifique (FR)
5 shared publications
- Loss of SUMO-specific protease 2 causes isolated glucocorticoid deficiency by blocking adrenal cortex zonal transdifferentiation in mice
- L’excès de SUMOylation altère l’homéostasie postnatale du cortex surrénalien et conduit à un déficit isolé en glucocorticoïde
- Loss of SUMO-specific protease 2 causes isolated glucocorticoid deficiency by blocking adrenal cortex zonal transdifferentiation
- Loss of SUMO-specific protease 2 causes isolated glucocorticoid deficiency by blocking adrenal cortex zonal transdifferentiation
- Loss of SUMO-specific protease 2 leads to adrenal insufficiency limited to glucocorticoids
Similar Researchers
Based on overlapping research topics
Ashira Thadisena
University of Arkansas for Medical Sciences
Metabolism and Genetic Disorders
Disease Mechanisms Research
Cardiovascular Function and Risk Factors
Jacob L. Edmondson
University of Arkansas for Medical Sciences
Metabolism and Genetic Disorders
Disease Mechanisms Research
Cancer-related molecular mechanisms research
Gaëtane Ternier
University of Arkansas at Fayetteville
Metabolism and Genetic Disorders
Disease Mechanisms Research
Cancer-related molecular mechanisms research
Srihari Shankar
University of Arkansas for Medical Sciences
Ubiquitin and proteasome pathways
Metabolism and Genetic Disorders
Cancer-related molecular mechanisms research
Michelle A. Johnson
University of Arkansas at Fayetteville
Metabolism and Genetic Disorders
Disease Mechanisms Research
Neuroscience and Neuropharmacology Research
Rahul Sharma
University of Arkansas for Medical Sciences
Metabolism and Genetic Disorders
Disease Mechanisms Research
Cancer-related molecular mechanisms research